Zusammenfassung
Osteoprotegerin (OPG), Receptor activator of nuclear factor kappaB (RANK) und dessen Ligand (RANKL) werden nicht nur als Schlüsselregulatoren des Knochenstoffwechsels beschrieben, sondern auch als wichtige Regulatoren immunologischer Funktionen erkannt. Eine koronare Herzerkrankung (KHK) entwickelt sich über Jahre und ist sehr oft die Folge entzündlicher Prozesse, die eine Schädigung des Endothels verursachen. Die rezente Literatur beschreibt OPG bei Patienten mit einer KHK als wichtigen Prädiktor von Mortalität und Morbidität.
Summary
Initially described as key regulators in metabolic bone disease osteoprotegerin (OPG), receptor activator of nuclear factor kappa B (RANK) and RANK ligand (RANKL) have also been discriminated as regulators in immunologic function. Cardiovascular diseases (CVD) develop over many years in life and are often triggered by inflammatory processes within the vessel wall that lead to vascular remodeling. Recently some study groups have described OPG as a prognostic parameter for mortality and morbidity in cardiovascular patients.
References
Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein Involved in the regulation of bone density. Cell, 89: 309–319, 1997
Tsuda E, Goto M, Mochizuki S-I, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun, 234: 137–142, 1997
Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 139: 1329–1337, 1998a
Kwon BS, Wang S, Udagawa N, et al. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J, 12: 845–854, 1998
Tan KB, Harrop J, Reddy M, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and no-hematopoietic cells. Gene, 204: 35–46, 1997
Yun TJ, Chaudhary PM, Shu GL, et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol, 161: 6113–6121, 1998
Yun TJ, Tallquist MD, Aicher A, et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol, 166: 1482–1491, 2001
American Society for Bone and Mineral Research President's Committee on Nomenclature. Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. Bone, 27: 761–764, 2000
Hilton MJ, Gutierrez L, Zhang L, et al. An integrated physical map of 8q22-Q24: use in positional cloning and deletion analysis of Langer-Giedion syndrome. Genomics, 71: 192–199, 2001
Morinaga T, Nakagawa N, Yasuda H, et al. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. Eur J Biochem, 254: 685–691, 1998
Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci, 95: 3597–3602, 1998b
Merewether LA, Le J, Jones MD, et al. Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. Arch Biochem Biophys, 375: 101–110, 2000
Tomoyasu A, Goto M, Fujise N, et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun, 245: 382–387, 1998
Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem, 273: 5117–5123, 1998
Leibbrandt A, Penninger JM. RANK/RANKL: Regulators of immune responses and bone physiology. Ann NY Acad Sci, 1143: 123–150, 2008
Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene, 17: 3261–3270, 1998
Lacey DL, Timms E, Tan H-L, et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93: 165–176, 1998
Emery JG, McDonnell P, Brigham Burke M, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 273: 14363–14367, 1998
Wagner D, Fahrleitner-Pammer A. Levels of osteoprotegerin (OPG) and receptor activator for factor kappa ligand (RANKL) in serum: are they of any help. Wien Med Wochenschr, 160: 452–457, 2010
Fahrleitner-Pammer A, Herberth J, Browning SR, et al. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res, 23: 1850–1858, 2008
Fuller K, Wong B, Fox S, et al. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med, 188: 997–1001, 1998
Quinn JMW, Elliott J, Gillespie MT, et al. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology, 139: 4424–4427, 1998
Udagawa N, Takahashi N, Jimi E, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-κb ligand. Bone, 25: 517–523, 1999
Xu J, Tan JW, Huang L, et al. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-κb ligand. J Bone Miner Res, 15: 2178–2186, 2000
Dobnig H, Hofbauer LC, Viereck V, et al. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in biphosphanate-treated osteoporotic patients. Osteoporos Int, 17: 693–703, 2006
Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 12: 1260–1268, 1998
Venuraju SM, Yerramasu A, Corder R, et al. Osteprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol, 55: 2049–2061, 2010
Price P, June HH, Buckley JR, et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin B. Arterioscler Thromb vasc Biol, 21: 1610–1616, 2001
Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun, 247: 610–615, 1998
Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(–/–) mice. Circulation, 117: 411–420, 2008
O'Sullivan EP, Ashley DT, Davenport C, et al. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. Diabetes Metab Res Rev, 26: 496–502, 2010
Zagura M, Serg M, Kampus P, et al. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens, 23: 586–591, 2010
Crisafulli A, Micari A, Altavilla D, et al. Serum level of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clinical Science, 109: 389–395, 2005
Osako MK, Nakagami H, Koibuchi N, et al. Estrogen inhibits vascular calcification via vascular RANKL systems. Common mechanism of osteoporosis and vascular calcification. Circ Res, 107: 466–475, 2010
Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentration in postmenopausal women with osteoporosis. J Bone Miner Res, 14: 518–527, 1999
Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation, 109: 2175–2180, 2004
Clancy P, Oliver L, Jayalath R, et al. Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler Thromb Vasc Biol, 26: 2574–2576, 2006
Gogo P, SSchneider DJ, Terrien EF, et al. Osteoprotegerin is not associated with angiographic coronary calcification. J Thromb Thrombolysis, 22: 177–183, 2006
Sandberg WJ, Yndestad A, Oie E, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome. Possible role in plaque destabilization. Arterioscler Thromb Vasc Biol, 26: 857–863, 2006
Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care, 29: 1664–1666, 2006
Rasmussen LM, Tarnow L, Hansen TK, et al. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrin, 154: 75–81, 2006
Xiang G, Xu L, Zhao LS, et al. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes, 55: 2126–2131, 2006
Anand DV, Lahiri A, Lim E, et al. The Relationship between plasma Osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. JACC, 47: 1850–1857, 2006
Avignon A, Sultan A, Piot C, et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemic in asymptomatic diabetic patients. Diabetes Care, 30: 2934–2939, 2007
Xiang GD, Xu L, Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Zhonghua Yi Xue Za Zhi, 87: 1234–1237, 2007
Anand DV, Lim E, Darko D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes. Role of glycemic control and inflammatory/vascular calcification markers. JACC, 50: 2218–2225, 2007
Asanuma Y, Chung CP, Oeser A, et al. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 195: e135–e141, 2007
Abedin M, Omland T, Ueland T, et al. Relation of osteoprotegerin to coronary calcium and aortic plaques (from the DALAS heart study). Am J Cardiol, 99: 513–519, 2007
Helske S, Kovanen PT, Lindstedt KA, et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular overload. Eur J Heart Fail, 9: 357–363, 2007
Omland T, Drazner MH, Ueland T, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension, 49: 1392–1398, 2007
Kiechl S, Schett G, Schwaiger J, et al. Soluble Receptor activator of nuclear factor-B ligand and risk for cardiovascular disease. Circulation, 116: 385–391, 2007
Kadoglou NP, Gerasimidis T, Golemati S, et al. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg, 47: 55–62, 2008
Siepi D, Marchesi S, Vaudo G, et al. Preclinical vascular damage in white postmenopausal women: the relevance of osteoprotegerin. Metab Clin Exper, 57: 321–325, 2008
Golledge J, Leicht AS, Crowther RG, et al. Determinants of endothelial function in a cohort of patients with peripheral artery disease. Cardiology, 111: 51–56, 2008
Semb AG, Ueland T, Aukrust P, et al. Osteoprotegerin and soluble receptor activator of nuclear factor- B ligand and risk for coronary events. A nested case-control approach in the prospective EPIC- Norfolk population study 1993–2003. Artherioscler Thromb Vasc Biol, 29: 975–980, 2009
Kong Y-Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397: 315–323, 1999a
Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab, 88: 1024–1028, 2003
Gannage-Yared MH, Fares F, Semaan M, et al. Circulation Osteoprotegerin is correlated with lipid profile, insulin sensivity, adiponectin and sex steroids in an ageing male population. Clin Endocrin (Oxf), 64: 652–658, 2006
Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 106: 1192–1194, 2002
Khosla S, Arrighi HM, Melton LJ 3rd, et al. Correlates of osteoprotegerin levels in women and men. Osteopor Int, 13: 394–399, 2002
Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet, 358: 257–259, 2001c
Ho KK, Anderson KM, Grossman W, et al. Survival after the onset of congenitiv heart failure in Framingham heart study. Circlation, 88: 107–115, 1993
Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res, 91: 988–998, 2002
Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol, 274: R577–595, 1998
Yndestad A, Damas JK, Geir EH, et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res, 54: 175–182, 2002
Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation, 111: 2461–2468, 2005
Yan ET, Yan RT, Spinale FG, et al. Relationship between plasma levels of matrix metalloproteinase and neurohormonal profile in patients with heart failure. Eur J Heart Fail, 10: 125–128, 2008
Liu W, Feng W, Wang F, et al. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Exp Mol Pathol, 84: 213–217, 2008
Omland T, Ueland T, Jansson AM, et al. Circulation osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol, 51:627–633, 2008
Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol, 44: 1970–1976, 2004
Roysland R, Masson S, Omland T, et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. Am Heart J, 160: 286–293, 2010
Lieb W, Gona P, Larson MG, et al. Biomarkers of osteoprotegerin pathway clinical correlates, subclinical disease, incident cardiovascular disease and mortality. Arterioscler Thromb Vasc Biol, 30: 1849–1854, 2010
Ueland T, Dahl CP, Kjekshus J, et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail, 4(2): 145–152, 2011
Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol, 143: 31–48, 2007
Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrin, 159: 603–608, 2008
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Malliga, DE., Wagner, D. & Fahrleitner-Pammer, A. The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology – a review. Wien Med Wochenschr 161, 565–570 (2011). https://doi.org/10.1007/s10354-011-0022-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10354-011-0022-7